Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

ABSTRACT:

Background

Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven.

Objectives

To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone.

Methods

A total of 250 patients with surgically unsalvageable giant cell tumor of bone were included in this randomized clinical trial. Patients received either subcutaneous denosumab (DB group; 120 mg per 4 weeks plus an additional 120 mg on days 8 and 15; n = 125) or intravenous zoledronic acid (ZA group; 4 mg per 4 weeks; n = 125) for six cycles. Disease status, clinical benefits, treatment-emergent adverse effects, overall survival, and cost of treatment were

SUBMITTER: Li S 

PROVIDER: S-EPMC6357891 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature